tetano
Editor, Senior Moderator
Expert Rev Vaccines
. 2020 Sep 23.
doi: 10.1080/14760584.2020.1825946. Online ahead of print.
"Mindful" development of rapid, safe and effective COVID-19 vaccines
Leonard Moise[SUP] 1 2 [/SUP], Ted M Ross[SUP] 3 [/SUP], Daniel F Hoft[SUP] 4 [/SUP], William D Martin[SUP] 1 [/SUP], Anne S De Groot[SUP] 1 3 [/SUP]
Affiliations
Abstract
The world needs a vaccine urgently to recover from the COVID-19 pandemic. In the race to a vaccine, several companies and funders are pursuing the most obvious approach, which is to develop antibody-focused vaccines based on the SARS-CoV-2 spike glycoprotein antigen. Emphasis on one approach, while setting aside others, is no small gamble. We believe the urgency of the situation calls for pursuit of multiple paths to a safe and effective vaccine. T cell immunity is essential to resolve SARS-CoV-2 infection and is a critical component of immunity against related coronaviruses. A T cell-directed vaccine may stimulate viral clearance mechanisms that reduce morbidity and obviate the risk of antibody-dependent enhanced disease. Moreover, T cell-directed vaccines can be designed to recall memory against similar viruses and/or to stimulate immunity against SARS-CoV-2 and other highly pathogenic coronaviruses. Mindful development of T cell-epitope driven vaccines may help to protect against the current coronavirus outbreak and pathogenic coronaviruses that are likely to emerge and threaten humanity again.
Keywords: COVID-19; SARS-CoV-2; T cell; T cell epitope; antibody; coronavirus; vaccine.
. 2020 Sep 23.
doi: 10.1080/14760584.2020.1825946. Online ahead of print.
"Mindful" development of rapid, safe and effective COVID-19 vaccines
Leonard Moise[SUP] 1 2 [/SUP], Ted M Ross[SUP] 3 [/SUP], Daniel F Hoft[SUP] 4 [/SUP], William D Martin[SUP] 1 [/SUP], Anne S De Groot[SUP] 1 3 [/SUP]
Affiliations
- PMID: 32962468
- DOI: 10.1080/14760584.2020.1825946
Abstract
The world needs a vaccine urgently to recover from the COVID-19 pandemic. In the race to a vaccine, several companies and funders are pursuing the most obvious approach, which is to develop antibody-focused vaccines based on the SARS-CoV-2 spike glycoprotein antigen. Emphasis on one approach, while setting aside others, is no small gamble. We believe the urgency of the situation calls for pursuit of multiple paths to a safe and effective vaccine. T cell immunity is essential to resolve SARS-CoV-2 infection and is a critical component of immunity against related coronaviruses. A T cell-directed vaccine may stimulate viral clearance mechanisms that reduce morbidity and obviate the risk of antibody-dependent enhanced disease. Moreover, T cell-directed vaccines can be designed to recall memory against similar viruses and/or to stimulate immunity against SARS-CoV-2 and other highly pathogenic coronaviruses. Mindful development of T cell-epitope driven vaccines may help to protect against the current coronavirus outbreak and pathogenic coronaviruses that are likely to emerge and threaten humanity again.
Keywords: COVID-19; SARS-CoV-2; T cell; T cell epitope; antibody; coronavirus; vaccine.